Can a new pill wipe out hidden myeloma after transplant?
NCT ID NCT05434689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding iberdomide (a new oral drug) to standard treatments can eliminate tiny amounts of myeloma cells that remain after a stem cell transplant. About 80 adults with multiple myeloma who still have detectable cancer cells after transplant will receive one of several drug combinations. The goal is to see if these combinations can make the cancer undetectable and keep it away longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iberdomide (a new oral drug) combined with daratumumab, dexamethasone, or carfilzomib
What this could lead to
If successful, this could offer a way to eliminate remaining cancer cells after transplant, potentially leading to longer remission and better disease control for multiple myeloma patients.
What could go wrong
This is an early-phase trial with only 80 participants, so results may not apply broadly. The drug combinations may cause side effects or fail to clear residual disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Medical College
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States